The Balloon Catheters, which have diameters of 2.0, 2.5, 3.0 and 3.5 mm, features nitinol scoring elements which offer unique circumferential scoring of plaque, resulting in precise and predictable luminal enlargement across a wide range of lesion types.

The longer AngioSculpt catheters also have the ability to achieve a very low rate of dissection, potentially minimizing the need to perform adjunctive stenting, claims the company.

AngioScore president and CEO Thomas Trotter said the peripheral artery disease market is a rapidly growing segment of the interventional cardiovascular market.

"Over a million percutaneous peripheral procedures are now being performed annually worldwide, and the PAD market continues to demonstrate significant growth due to improved diagnosis and the increasing prevalence of important risk factors such as adult onset diabetes mellitus," Thomas added.

"We believe that the AngioSculpt line of Scoring Balloon Catheters is particularly useful in treating this very challenging and serious disease."

The new catheters are also FDA-approved for use in the dilatation of lesions in the iliac, femoral, iliofemoral, popliteal, infra-popliteal, and renal arteries, as well as for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae.

AngioScore said the AngioSculpt catheters are not labeled for use in the coronary or neuro-vasculature.